Helical Secures $10 Million for Virtual AI Lab in Pharmaceutical Research

Helical, a promising biotechnology company founded in early 2024, has announced the closure of a $10 million seed funding round. The investment was led by redalpine, with participation from Gradient, BoxGroup, and Frst, alongside several prominent angel investors, including Aidan Gomez (CEO of Cohere), Clement Delangue (CEO of Hugging Face), and Mario Götze. This capital is earmarked to bolster the development and expansion of its innovative virtual AI lab, designed to revolutionize research and development in the pharmaceutical sector.

Helical's mission is clear: to address and resolve one of the primary bottlenecks afflicting drug discovery—the limited throughput of physical experimentation. While biological foundation models enable scientists to computationally test hypotheses, many pharmaceutical teams still face challenges in translating these model outputs into reproducible and actionable scientific decisions.

The Platform: A Bridge Between Computation and Validation

Helical's platform aims to bridge this critical gap by providing an application layer that synergistically integrates computational predictions with biological validation. This approach seeks to create more efficient and collaborative research workflows, accelerating the entire discovery process.

At the core of Helical's offering is its virtual AI lab, designed to transform biological foundation models into reproducible discovery systems. The platform is structured into two interconnected components: the "Virtual Lab," tailored for biologists and translational scientists, and the "Model Factory," built for machine learning engineers and data scientists. By operating on shared data, models, and results, the platform facilitates collaboration across traditionally siloed teams, supporting evidence-based decision-making throughout the discovery journey. Rick Schneider, co-founder of Helical, emphasized that meaningful drug discovery is driven by systems that combine and operationalize model insights, rather than by models alone. He added: "Pharma teams need a system that turns foundation models into workflows scientists can run, validate, and defend. We built Helical to make in-silico science reproducible at pharma scale, so teams can go from hypothesis to decision in days instead of months."

Impact and Outlook in the Pharmaceutical Sector

Helical is already collaborating with several of the top twenty global pharmaceutical companies. The platform's applications range from target identification to biomarker discovery and therapeutic design. In these contexts, Helical's solution has significantly reduced discovery timelines and facilitated expansion into new therapeutic areas.

The pharmaceutical industry is characterized by rising research and development costs and extended timelines for drug market entry. In this scenario, Helical positions itself as a key enabler for enhancing the efficiency and reliability of drug discovery. For companies operating with sensitive data and stringent compliance requirements, adopting solutions like Helical's, which allow granular control over models and data, is of fundamental importance. This approach aligns with the needs for data sovereignty and controlled environments, often preferred for on-premise or hybrid deployments.

The Future of Funding and Expansion

The newly secured funds will be utilized to deepen deployments across therapeutic areas with existing clients and to expand engagement with additional pharmaceutical organizations. Another priority will be the further development of the platform's "evidence layer," with the goal of improving performance across various diseases.

This investment not only validates Helical's approach but also underscores the growing demand for AI tools that can accelerate complex and costly processes such as drug discovery. For CTOs and infrastructure architects in the pharmaceutical sector, the ability to integrate such platforms into local stacks or hybrid environments, while maintaining data sovereignty and optimizing TCO, represents a crucial strategic consideration. AI-RADAR offers analytical frameworks on /llm-onpremise to evaluate the trade-offs between self-hosted and cloud solutions, an increasingly relevant aspect in contexts like pharmaceutical research.